text:
What opportunities get created as fields converge? What challenges surface as markets, policies, and investing dynamics shift? What new scientific discoveries are potential game-changers? Convergence exists to explore those questions (and many others), with a high-level audience interested in what's happening in the rapidly-converging worlds of biotech, pharma, healthcare, medical devices, and the Internet.
The Convergence Forum fosters real debate and discussion among audiences that are every bit as high-level as the speakers. The programs provide an opportunity for participants to make important new contacts, do business, explore important new directions in research, delve deeply into what it takes to maintain competitive advantage in a fast-changing world, and leave feeling recharged.
Bring together high-level healthcare players to discuss and debate the most pressing topics of interest to the industry. Create useful connections and relationship. Help companies big and small succeed.
What Makes It Different
Our programs deliver a rapid-fire stream of ideas, advice, lessons-learned, and important insights – not a parade of 15-minute company presentations. They are not your typical investor conferences – they are inivitation-only gatherings designed for people who make news in healthcare innovation. The program is specifically designed to also allow time and space to foster deals among participants.
Life sciences executives and company founders; heads of R&D; strategy executives and insurers; hospital research, innovation and licensing executives, chief business officers; venture capitalists; investment bankers; and partnership execs at pharmaceutical companies.
Participants will exchange ideas with industry leaders, develop useful connections with a select group of colleagues, and lay the foundation for future business dealings.
Press Policy
Convergence asks those of its participants who are journalists or bloggers to adhere to our "off-the-record" policy.
What does "off-the-record" mean, in our definition? If a speaker or moderator requests that a given comment or presentation be kept "off-the-record," we ask you to respect that and not share it with those outside the room. Otherwise, feel free to blog, report, or Tweet.
A limited number of press passes are issued each year, and by accepting a press pass to the event, the conference organizers expect that the recipient will adhere to this policy.
About the Organizers
Convergence is the high-level gatherings produced by Future Forward Events, LLC. Since 2000, our programs, which also include the Nantucket Conference and Future Forward, have assembled innovators and change agents from various fields — people as diverse as John Abele, co-founder of Boston Scientific; inventor and futurist Ray Kurzweil; genomics pioneer J. Craig Venter; Google CEO Eric Schmidt; Ethernet inventor Bob Metcalfe; Craigslist CEO Jim Buckmaster; Genzyme CEO Henri Termeer; medical device entrepreneur Dean Kamen; and Doug Melton of the Harvard Stem Cell Institute.
Convergence is designed, programmed, and run by a group of people who are committed to the life sciences sector. The Advisory Board for Convergence Forum includes:
Steve Dickman - CEO, CBT Advisors
Steve Dickman is CEO of CBT Advisors (www.cbtadvisors.com), a life sciences consulting firm in Cambridge, Massachusetts. Steve Dickman knows both sides of the dealmaking process. A former VC and writer with Nature and The Economist who has been in consulting for the past ten years, he applies sharp analytical skills and deep industry experience in conducting the right expert interviews, creating the right materials and telling the right stories on behalf of his clients. Steve has worked with biotech, diagnostics and medical device firms as well as top-tier VC funds.
Steve publishes a well-regarded industry blog, Boston Biotech Watch (http://bostonbiotechwatch.com), that tracks biotech, VC and technology trends.
Before founding CBT Advisors in 2003, Mr. Dickman spent four years in venture capital with TVM Capital. There, Mr. Dickman's deals included Sirna Therapeutics, sold to Merck in 2006 for $1.1 billion and Genetix Pharmaceuticals, later renamed bluebird bio, which IPO'd on Nasdaq in 2013.
Shayne Gilbert - Founder, Silverweave; author, 90 Days to Launch
Shayne Gilbert has been fueling the entrepreneurial community since starting Silverweave in 1994. Through Future Forward Events, Shayne creates exclusive programs for high technology and life sciences executives and investors including the Nantucket Conference for technology executives and investors and Convergence: the Life Sciences Leaders Forum for the life sciences industry. Future Forward Events has produced programs on both the East and West coasts as well as internationally.
Given her ability to remain close to the pulse of New England's emerging businesses, Shayne is often sought to contribute and comment on the impact of the growth of technology and life sciences industries in New England. This work has included Mass Impact: An Upcoming Report on the Growth and Health of the Life Sciences Industry in Massachusetts, on behalf of MIT, and the executive summaries for Engines of Economic Growth: The Economic Impact of Boston's Eight Research Universities on the Metropolitan Boston Area, produced in 2003 and Entrepreneurial Impact: The Role of MIT in 2008.
The author of 90 Days to Launch (Wiley, 2000), Shayne's work has been recognized in The Wall Street Journal, the Boston Globe and Wired.
Shayne is also a founder of Campseekers, a clearinghouse for the 90% of camps that don't reach capacity in this $15 billion industry.
A graduate of Wellesley College and the Kellogg Graduate School of Management at Northwestern University, Shayne lives in Boston with her husband and daughter.
Colin Hill - CEO, GNS Healthcare
Colin Hill co-founded GNS Healthcare in 2000 and has served as CEO since then. He also serves as Chairman of GNS Healthcare's parent company Via Science, a leading big data analytics company focused on business intelligence, finance, and economic forecasting. Colin is a frequent speaker at international scientific and industry conferences and serves as co-chair of O'Reilly Media's Strata Rx healthcare Big Data conference. He has appeared in numerous publications and television segments including The Wall Street Journal, CNBC Morning Call, Nature, Forbes, Wired, and The Economist, and is the author of the "Healthcare 2020" blog on Forbes.com. He also serves on the board of directors of AesRx, a biopharmaceutical company dedicated to the development of a new treatment for sickle cell disease, on the advisory board of the Boston Medical Center's philanthropic trust, and as the chair of the industrial advisory board of EBICS.
In 2004, Colin was named to MIT Technology Review's TR35 list of the top innovators in the world under the age of 35. He graduated from Virginia Tech with a degree in physics and earned master's degrees in physics from McGill University and Cornell University.
Jeff Jonker - President, NGM Biopharmaceuticals, Inc.
Prior to joining NGM, Jeff was the Senior Vice President, Corporate and Business Development at Theravance Biopharma (NASDAQ: TBPH) and held that same role at Theravance, Inc. (NASDAQ: THRX) prior to the spin-out of TBPH. He previously served as the Chief Business Officer of Satori Pharmaceuticals, the Vice President of Business Development and Corporate Strategy for Gloucester Pharmaceuticals prior to its acquisition by Celgene (NASDAQ: CELG) and leadership positions in the business development and legal groups at Genentech. Prior to Genentech, Jeff was an associate in the Technology Transactions Group at Wilson, Sonsini, Goodrich & Rosati, representing clients in the life science and high tech industries. Jeff holds a J.D. from Columbia University School of Law, an M.LITT. from the University of St. Andrews and a B.A. from Claremont McKenna College.
Scott Kirsner - Innovation Economy columnist, Boston Globe
Scott Kirsner is the "Innovation Economy" columnist at the Boston Globe and he writes the blog Innovation Economy (www.boston.com/innovation), and is the author of the book "Fans, Friends & Followers." His technological history of Hollywood, "Inventing the Movies," was published in 2008. Scott's writing has also appeared in the New York Times, The Hollywood Reporter, Variety, BusinessWeek, the San Jose Mercury News, the San Francisco Chronicle, andNewsweek, among other publications. Scott is a frequent moderator and event host, and is also one of the founders of the annual Nantucket Conference on Entrepreneurship and Innovation (www.nantucketconference.com), Convergence: The Life Sciences Leaders Forum (www.convergenceforum.com), and Future Forward: The New England Technology Summit (www.futureforward.com). He is a graduate of Boston University's College of Communications and the New World School of the Arts, in Miami. He can be reached at email@example.com.
Rich Kivel - Entrepreneur & Investor
Business leader who rapidly assesses investment and business opportunities and builds value through disciplined execution of strategic corporate development and operating plans. Global Operations & Finance Executive, Board Chairman, Trustee, Advisor, International Speaker & Presenter, Innovation Thought leader, Serial Entrepreneur. Global network of business, financial, government and institution contacts.
Current Boards: Executive Chair, ViS Research Institute; Trustee, Fundación Innovación Bankinter; Director, Baufest, Director, Rexahn Pharmaceuticals (NYSE: RNN); Co-Founder/Chair, Rhapsody Biologics.
Corporate: Senior Advisor G3; Senior Manager, Hedge Fund Bridgewater Associates; Founding-CEO, Rhapsody Biologics; CEO, TheraGenetics; CEO, MolecularWare; VP, Interliant.
Extensive experience with private and public company investors, PE firms, Venture Capital and Investment Banks. Frequent speaker and panelist at major economic forums, investor and industry conferences.
Entrepreneur: Passionate about developing high-growth global companies and creating value through technology and financial transactions.
Business Builder and Investor: Maintain strong relationships with private and public investors, analysts and bankers to generate investment thesis, innovative ideas and strategies, that position companies for growth and expansion. Focused on engineer M&A transactions, investor funding, corporate carve-out's, IPOs and turnarounds.
Academia: MIT: MIT Enterprise Forum Chair & President; MIT Alumni Association Director; Innovation and Entrepreneurship Lecturer; MIT $100K Entrepreneurship Competition Judge; Deshpande Center for Technological Innovation Catalyst; Frontier Research Fund & Bridge Project, MIT Koch Institute for Integrative Cancer Research Supporter.
Reid Leonard PhD - Vice President, Corporate Development, POTENZA Therapeutics
Presently, VP of Corporate Development at POTENZA Therapeutics, an early-stage research and development company focused on creating novel immunotherapies for cancer.
From 2012-2014, Managing Director at MRL Ventures (MRLV), the strategic venture capital group of Merck Research Laboratories.
Prior to joining MRLV, Reid spent 15 years in Merck Licensing & External Scientific Affairs, most recently as Executive Director for scientific search & evaluation in Boston, Massachusetts.
Reid started his career at Merck as a discovery scientist working on structure and function of ion channels, cellular excitability, and membrane signaling in support of a variety of therapeutic programs.
A graduate of Brandeis University (B.A., biology & psychology), and Purdue University (Ph.D., neuroscience), Reid completed his academic training as a postdoctoral fellow in molecular pharmacology and physiology at the California Institute of Technology.
Douglas MacDougall - President, MacDougall Biomedical Communications, Inc.
Douglas MacDougall is the founder and President of MacDougall Biomedical Communications (www.macbiocom.com) – a firm with offices in Boston, San Francisco and Munich dedicated to building visibility and valuation for public and private life-science companies. Doug has been actively involved in the biotechnology industry for over 27 years and has provided strategic communications counsel and developed corporate communications plans for over 300 clients in the life-science space. He speaks on topics related to investor relations and media relations and facilitates corporate positioning meetings for many leading biotech companies each year. Doug is the founder and chairperson of the BIO Executive Workshop Series that has trained over 1200 CEO's in the US, Europe and Australia on "Effectively Communicating with Investors." Doug also assists many of his clients in fundraising activities and is a member of the MIT Venture Mentoring Service and an Overseer at the Boston Museum of Science.
Doug was most recently Chief Financial Officer of Cetek Corporation and prior to that, Senior Vice President at Feinstein Kean Healthcare (FKH) where he built innovative corporate communications and investor relations programs for its biotechnology clients over a six year period. Before joining FKH, Doug was Vice President of Finance and Administration of publicly held Applied DNA Systems for a period of six years. Doug has a BS in Business Administration from Rochester Institute of Technology.
Bruce Rychlik - Managing Partner, Park Square Executive Search
Bruce Rychlik is a co-founder and Managing Partner of Park Square Executive Search. With over twenty years in the search profession, Bruce Rychlik's recruiting practice focuses on life sciences, specifically Chief Executive Officers as well as functional leaders—scientific, technical, clinical, financial and business development—at a national level. A majority of his searches involve venture-backed life science companies in the therapeutics, diagnostics and tools space.
Within life sciences, Bruce has also extensively recruited board members, venture capital professionals, and individuals for innovation/technology transfer initiatives at academic/research institutions. Throughout his career, he has also worked on numerous international recruiting projects throughout Asia, particularly Japan, as well as Europe.
Bruce is an Advisor to Convergence: The Life Sciences Leaders Forum, which hosts annual events in New England. He earned an M.B.A. from Boston University (1997) and a B.A. in Political Science from Dickinson College in Carlisle, Pennsylvania (1989). He lives with his wife Kristina, daughter Anna and sons Alexander and Robert in Acton, Massachusetts. Road cycling helps to fulfill his interests in exercise and nutrition, travel and the outdoors.
Alyssa Stern - Vice President, Future Forward Events, LLC
Alyssa Stern is the Vice President of Future Forward Events, LLC where she manages the high level programs operated by the company. The Nantucket Conference, launched in 2000, delivers an exclusive program for executives and investors in the region's emerging technology industries. Future Forward: The New England Technology Summit, introduced in 2001, brings together CIOs and other corporate technology influencers with the executives of emerging technology companies. Convergence: The Life Sciences Leaders Forum brings together executives and investors in the life sciences industry. In 2008, the company introduced The Conversation, a program series focusing on the future of entertainment. Today, the company annually produces events in New England, New York and California.
Alyssa is also Vice President of Silverweave Inc. As a program management consultant, she helped manage the launch of the MIT Biotech Forum and worked with the Deshpande Center on the Ideastream Symposium for a number of years.
Prior to Future Forward Events and Silverweave, Alyssa worked at Hay/McBer, a human resources consulting firm, as Manager of New Products and Services. She has managed training events and conferences since 1996. Alyssa received both her undergraduate degree and Masters in Business Administration from Boston University.
Alison Taunton-Rigby, PhD, OBE - Director & Trustee, Healthcare, Life Sciences and Financial
Alison Taunton-Rigby, Ph.D., O.B.E., has been President and Chief Executive Officer, of several public and private companies in the life science and healthcare industries. She currently serves as a Director on a number of public, private, non-profit, ESOP and mutual fund boards.
Dr. Taunton-Rigby was Founder, President and Chief Executive Officer of RiboNovix, Inc., a biotechnology company, President and Chief Executive Officer of Aquila Biopharmaceuticals, Inc., a public life sciences company that was merged in late 2000 with Antigenics Inc. She was also President and Chief Executive Officer of Cambridge Biotech Corporation, where she led the turn-around, re-structuring and emergence from bankruptcy. In addition, she has served as President and Chief Executive Officer of Mitotix Inc., merged with GPC Biotech. Previous to this position, she was Senior Vice President, Biotherapeutics, at Genzyme Corporation, where she had overall responsibility for Genzyme's biotherapeutics division. Dr. Taunton-Rigby has also served in senior management positions at Arthur D. little, Inc., Vivotech Inc., Biogen, Inc. and Collaborative Research, Inc.
Dr. Taunton-Rigby received her doctorate from the University of Bristol in England, and is a graduate of the Advanced Management Program of the Harvard Business School. She is a Director of Columbia Funds, Healthways, Inc., Abt Associates, Inc., Boston Children's Hospital, the Biomedical and Science Careers program, and the Massachusetts Women's Forum. She is also a member of the Business Advisory Council, Simmons College, School of Management, an Advisor to Civic Capital LLC, a member of Boston University School of Public Health, Health Policy and Management Advisory Board, and a former Director and Chair of the Massachusetts Biotechnology Council (MBC), and of the Biotechnology Industry Organization (BIO). In 2005 she was appointed to the Massachusetts Biomedical Research Advisory Committee (stem cell research) and in 2008 to the Scientific Advisory Board, Massachusetts Life Science Center. In 2002 Dr. Taunton-Rigby was awarded the OBE (Officer of the Order of the British Empire) by Queen Elizabeth II for her work as a leader in the research, development and promotion of biotechnology. In 2009 she was awarded an honorary D.Sc. by the University of Bristol, UK.
Jeff Walsh - Chief Operating Officer, Bluebird Bio
Jeff Walsh joined Bluebird Bio as Chief Operating Officer in May 2011. Jeff has 25 years of experience working with high-profile public and private life sciences companies, with responsibilities spanning the financial management, business development, program management, commercial development and legal functions. Before joining bluebird bio, Jeff was the chief business officer of Taligen Therapeutics where he led the financial management and corporate development of the company and played a key role in the growth of the company and the sale of Taligen to Alexion Pharmaceuticals in January 2011 for up to $478 million. Jeff started his career at SmithKline Beecham in finance and worldwide business development roles. He subsequently held senior-level business development, finance and operations roles at Allscripts (MDRX), PathoGenesis (PGNS sold to Chiron for $700 million), EXACT Sciences (EXAS) and Inotek Pharmaceuticals. Jeff received his M.B.A. from the Kellogg Graduate School of Management at Northwestern University and his B.A. from Yale University.
Advisors Emeritus
Mara Aspinall - President, Ventana Medical Systems; Global Head, Roche Tissue Diagnostics
Mara Aspinall is President and CEO of Ventana Medical Systems and Global Head of Roche Tissue Diagnostics. Ventana, a member of the Roche Group, is the worldwide leader in the development, manufacturing and commercialization of tissue-based cancer diagnostic instruments and products that enable the delivery of personalized healthcare to cancer patients.
Mara is also Founder and former CEO of On-Q-ity, a personalized medicine company focused on transforming cancer patient management through capture and characterization of circulating tumor cells (CTCs) in a patient's blood.
Previously, Mara was President of Genzyme Genetics, a leading provider of testing services in the oncology and reproductive markets. Under Mara's leadership, Genzyme Genetics set the industry standard for quality testing while profitably growing to become one of the nation's largest diagnostic laboratories. Before that, she served as President of Genzyme Pharmaceuticals.
An active participant in the healthcare policy community, Mara is a founding Director of the European Personalized Medicine Association (EPEMED) and a Director of the US Personalized Medicine Coalition (PMC). She served for four years on the Federal Health and Human Services Secretary's Advisory Committee on Genetics, Health and Society. Mara also lectures on life science issues at many institutions, including Harvard Medical School and Boston University School of Management, and was a Board Member of Blue Cross Blue Shield Massachusetts for three years.
Mara co-authored "Realizing the Promise of Personalized Medicine" in Harvard Business Review, and has written several articles, case studies and editorials on healthcare topics. In 2010 she was named one of the "100 Most Inspiring People in Life Sciences" by PharmaVOICE magazine.
Mara started her career at Bain & Company. She earned her MBA from Harvard Business School and her BA in International Relations from Tufts University.
Safi Bahcall, PhD - President and CEO, Synta Pharmaceuticals
Dr. Bahcall co-founded Synta and has been Chief Executive Officer since July 2001. Dr. Bahcall has led Synta from inception through multiple acquisitions, financings, an initial public offering, and the establishment of integrated, multi-product drug discovery and development organization. Prior to founding Synta, Dr. Bahcall was a consultant at McKinsey & Company advising investment banks and pharmaceutical companies on strategy, technology, and operations. Dr. Bahcall also co-founded a drug discovery company focused on novel ion channel research, now part of Synta. Dr. Bahcall received his B.A. summa cum laude in Physics from Harvard University, was awarded his Ph.D. from Stanford University in theoretical physics, and was a Miller postdoctoral fellow in condensed matter physics at U.C. Berkeley. In 2008, Dr. Bahcall was named Ernst & Young New England Biotechnology/Pharmaceutical Entrepreneur of the Year. He is currently a member of a working group on the future of the U.S. science and technology research enterprise, which consults with the President's Council of Advisers on Science and Technology (PCAST).
Joseph Baron - General Partner, Extera Partners LLC
Joseph is an experienced business development executive, and has closed deals for numerous emerging life science companies in the drug delivery, genomics, and medical device sectors. Prior to joining Extera Partners, Joseph started Adesso Systems and served as VP of Business Development. He raised over $6 million for Adesso, and acquired key customers like Novartis, GE Medical, HP, Lycos, and Intuit. Previously, he was a Senior Manager on Millennium Pharmaceuticals' M&A team, where he evaluated multiple acquisition opportunities for Millennium and helped close key partnerships with Abbott and Aventis. From 1994 to 1998, Joseph was an Associate at Booz Allen and Hamilton, developing market entry strategies for new life science companies and evaluating the effects of novel and disruptive technologies in the energy and chemicals markets. Joseph received a BS in Chemistry & Biochemistry with highest honors from WPI, an MS in Engineering with high honors from Stanford University, and an MBA from Harvard Business School. As part of his MBA, he worked at the Novartis Functional Genomics Center, evaluating market opportunities for plant-based vaccines.
Ansbert Gadicke, MD - Managing Director, MPM Capital
Dr. Ansbert Gadicke is a Co-Founder and Managing Director of MPM Capital. He led MPM's effort to build its Advisory and Investment Banking business from 1992 to 1996 and started its Asset Management business in 1996. MPM Capital is one of the world's largest dedicated investors in life sciences. With committed capital under active management in excess of $2.0 billion, MPM is uniquely structured to invest globally in healthcare innovation through its BioVentures family of venture capital funds.
Prior to founding MPM, Dr. Gadicke was employed by The Boston Consulting Group. Dr. Gadicke received an M.D. from J.W. Goethe University in Frankfurt. He subsequently held research positions in biochemistry and molecular biology at the Whitehead Institute at MIT, Harvard University and the German Cancer Research Center. He has published in leading scientific publications including Nature and Cell.
Dr. Gadicke is a Director of Cerimon Pharmaceuticals; Dragonfly Sciences; Radius Health; Solasia Pharma K.K., Tokyo; and Verastem, Inc. He previously served as a Director of Arriva Pharmaceuticals, BioMarin, Biovitrum, Coelacanth, Idenix, Kourion, MediGene, Omrix Biopharmaceuticals, Pharmasset, Inc.; PharmAthene, Transform, Xanodyne Pharmaceuticals, and ViaCell. He is a member of the Board of Fellows of Harvard Medical School.
Robert Gould - President and CEO, EpiZyme Inc.
Robert joined Epizyme as President and CEO in March, 2010, from the Broad Institute of MIT and Harvard, Cambridge, MA, where he was Director Novel Therapeutics. He has been a member of Epizyme's board of directors since 2008. He brings extensive experience and a demonstrated track record of success in the pharmaceutical industry.
At the Broad Institute, Robert built and set the strategic vision for Novel Therapeutics and participated in raising more than $100 million in research funding.
Prior to the Broad, Robert held a variety of leadership positions during 23 years at Merck, where he was instrumental in shepherding more than 20 compounds from discovery into clinical development and market in multiple therapeutic areas. He also spearheaded strategic initiatives for licensing and external research, as well as overseeing the Ophthalmic Worldwide Business Strategy Team.
Robert obtained degrees from Spring Arbor College, Michigan and The University of Iowa and undertook post-doctoral studies at The Johns Hopkins University and has published over 90 peer-reviewed publications and 16 patents. He currently serves on the Scientific Advisory Board for the Michael J. Fox Foundation and the Dean's Advisory Board for the University Of Iowa Carver College Of Medicine.
Michael Hanewich - Head of Life Sciences and Life Science Venture Capital on the East coast and Europe, Silicon Valley Bank
Michael Hanewich is Head of Life Sciences and Life Science Venture Capital on the East Coast and Europe for Silicon Valley Bank. Based in Boston, he is responsible for developing and maintaining relationships with venture capital companies, entrepreneurs, as well as accounting and law firms within the life science industry. Hanewich also leads the Life Science Practice in his role as national life sciences coordinator for the company. He has more than 25 years of commercial banking experience and extensive expertise of working with life science companies.
Before joining Silicon Valley Bank in 1999, Hanewich was an executive vice president for Flagship Bank and Trust Company for 10 years. He was instrumental in developing its biotechnology business and provided its clients with the proper financing and treasury management services needed to grow their businesses. Before joining Flagship Bank and Trust, Hanewich was with the Dun & Bradstreet Corporation for six years.
Hanewich is a member of The board of directors of The American Pain Foundation in Baltimore, Md., and a member of the New England Healthcare Institute in Cambridge, Mass. He holds a bachelor's degree from Eckerd College in St. Petersburg, Fla., and a master's degree from The Stonier Graduate School of Banking. Hanewich is also a member of the Eckerd College Athletic Hall of Fame (baseball).
Maggie Leflore, PhD - Venture Partner, MedImmune Ventures, Inc.
Maggie joined MedImmune Ventures as a managing director in 2007, moving into a Venture Partner role in 2011.She was previously Head of R&D Ventures at AstraZeneca, during which time she spent two years on assignment to Advent International working with their Healthcare and Life Sciences venture capital investment team. From 2001 to 2005, Maggie was the Global Alliance Director for Global Sciences and Information at AstraZeneca, where she led an international group responsible for evaluation, negotiation and management of global technology platform collaborations. From 1985 to 2001, Maggie held business development and scientific management positions at Hybridon, OSI Pharmaceuticals and Marion Merrell Dow Pharmaceuticals.
Maggie originally trained as a biophysical chemist, earning a B.S. in Chemistry from the University of Kansas and a Ph.D. in Physical Chemistry from Indiana University. She then trained in molecular and cellular biology as a post-doctoral fellow at the National Institutes of Health.
Frank Moss, PhD - Cofounder, Infinity Pharmaceuticals; Director, MIT Media Lab
Frank Moss is Professor of the Practice at the MIT Media Lab, where he heads the New Media Medicine group, and co-founder of Bluefin Labs, Inc. He has spent his career developing innovative technologies and bringing them to market. He was Director of the MIT Media Lab from 2006-2011, where he held the Jerome Wiesner chair of Media Technology, and before that he had a 30-year career as an entrepreneur in the software and computer industries. Moss served as CEO and chairman of Tivoli Systems Inc., a pioneer in distributed systems management, which he took public in 1995 and subsequently merged with IBM in 1996. He co-founded several other companies including Stellar Computer, Inc., a developer of graphic supercomputers, Bowstreet, Inc., a pioneer in the emerging field of web services, which was also acquired by IBM, and Infinity Pharmaceuticals, an early stage cancer drug discovery company (NASDAQ: INFI). Moss holds a BSE from Princeton University in Aerospace and Mechanical Sciences and a PhD from MIT in Aeronautics and Astronautics. He serves on the board of trustees of Princeton, where he is also a member of the School of Engineering and Applied Sciences leadership advisory council; and he also serves on the advisory council of the Mayo Clinic Innovation Center.
Stuart Randle - President and CEO, GI Dynamics
Stuart Randle is a seasoned executive with over 20 years experience in the life sciences industry. He joined GI Dynamics in 2004, and the company has since raised more than $75 million in venture financing, and strategic investments by Johnson & Johnson and Medtronic. During his tenure as CEO, GI Dynamics has made significant clinical progress with its EndoBarrier technology platform for the treatment of type 2 diabetes and obesity. Prior to GI Dynamics, he was an Entrepreneur in Residence at Advanced Technology Ventures. Previously, Stuart served as president and CEO at ACT Medical, Inc., where he implemented a strategic repositioning of the company that resulted in the acquisition by MedSource Technologies in 2001. Prior to ACT, Stuart was corporate officer at Allegiance Healthcare Corporation, where he was integral to the successful spin-off of Allegiance from Baxter International. Stuart started his career at Baxter Healthcare where he spent 10 years in various senior management positions. Stuart earned an MBA from The Kellogg Graduate School of Management at Northwestern University and a BS in Mechanical Engineering from Cornell University. He is a Trustee of the Cotting School, America's first school for children with disabilities, and is a member of the Board of Directors of The Advanced Medical Technology Association (AdvaMed) and Teleflex, Inc.
Jonathan Rosen, PhD - Executive Director, Institute for Technology Entrepreneurship and Commercialization (ITEC), Boston University School of Management; Senior Advisor to the Director, CIMIT
Jonathan Rosen is a member of theHarvard Medical School faculty, a Senior Research Scientist at theMassachusetts General Hospital, and directs the research implementation program for the CIMIT Consortium. Dr. Rosen received his Ph.D. in Biomaterials Science and Bioengineering from Case Western Reserve University and his MBA in Strategic Planning from Columbia University. During his corporate career with Johnson & Johnson, he managed the cardiovascular development program, directed the corporate advanced research program for their Corporate Office of Science and Technology, and served as Chief Technical Officer for their Surgical Instrument Division before leaving to start a series of medical device ventures in Europe and in the US. The Office of Technology Implementation works with collaborative teams of clinicians, engineers and scientists funded by the CIMIT Consortium to create and manage their intellectual property portfolios, identify and establish corporate partnerships, and design and implement innovative new business models.
Una Ryan, PhD, OBE - CEO, Diagnostics For All
Dr. Ryan is President and CEO of Diagnostics for All, a non-profit focused on low cost, easy to use diagnostics for the developing world.
Dr. Ryan was formerly President and CEO of Waltham Technologies, Inc and before that she was president and CEO of AVANT Immunotherapeutics, Inc. a publicly traded (NASDAQ) biopharmaceutical company developing vaccines.
Dr. Ryan is also Research Professor of Medicine at Boston University School of Medicine. She serves on the board of AMRI (NASDAQ), IQuum, and MHS (Management Sciences for Health). She is a member of the Massachusetts Life Sciences Collaborative Leadership Council, Goddard Council on science, technology, engineering and mathematics education and the Massachusetts Climate Change and Green Economy Council.
Dr. Ryan holds a Ph.D. in Cellular and Molecular Biology from Cambridge University and BS degrees in Zoology, Microbiology and Chemistry from Bristol University. In 2009 she received an Honorary Doctor of Science degree from Bristol University and the Cartier Women's Initiative Award. In 2007, she received the Albert Einstein Award for outstanding achievement in the life sciences. In 2002 Her Majesty Queen Elizabeth II awarded Dr. Ryan the Order of the British Empire (OBE) for her services to biotechnology.
John Santini, PhD - President and CEO, MicroCHIPS, Inc.
John Santini is an entrepreneur, scientist, and founder of MicroCHIPS with over a decade of experience in drug delivery and biosensing. Under Dr. Santini's leadership, MicroCHIPS has achieved a number of significant milestones including fundraising from top tier venture capital and corporateinvestors and the first long-term in vivo demonstration of an implantable drug delivery microchip. He is a recognized expert on the use of microtechnology in healthcare and has authored or co-authored over 60 issued/pending patents and several technical papers. Dr. Santini was honored by Technology Review Magazine as one of the Top 100 Young Innovators in the world. Prior to founding MicroCHIPS, he obtained his PhD in chemical engineering in the laboratories of Professors Robert Langer and Michael Cima at MIT as a National Science Foundation Fellow. Dr. Santini also graduated with a BSE in chemical engineering from theUniversity of Michigan.
Scott Sarazen - Global Biotechnology Markets Leader, Ernst & Young
Scott Sarazen is a Global Biotechnology Markets Leader at Ernst & Young.
Previously, Mr. Sarazen served several clients as a strategic consultant in support of biopharmaceutical business development initiatives. Prior to this role, Scott headed up Corporate Development at Straumann USA, a leading provider in the fields of implant dentistry and dental tissue regeneration. Mr. Sarazen was previously Senior Vice President, Life Sciences for MassDevelopment with the responsibility of enabling the retention and expansion of the Biotechnology, Pharmaceutical and Medical Device sectors in Massachusetts. And prior to joining MassDevelopment, Scott held the position of Director of Master Planning and Development for Genzyme Corporation. This role included both physical plant and product capacity planning.
Mr. Sarazen has over 18 years experience in strategic planning and business development, working in sectors as diverse as Engineering, Operations, Government, Biotechnology and Medical Devices. Scott has a B.S. in Engineering from Worcester Polytechnic Institute and a M.S. in Management from Lesley University.
In addition to other professional affiliations, Mr. Sarazen serves on the advisory boards of: the Harvard-MIT Division of Health Sciences and Technology (HST); the United Way's Math, Science & Technology After-School Initiative; the City of Boston's Life-Tech Initiative; and Convergence – the Life Sciences Leaders Forum.
Lauren Silverman PhD - Managing Director, Novartis Venture Funds
Prior to joining the Venture Fund she was Global Head of Oncology Research Operations for Novartis. Previously, Lauren spent much of her career in Licensing & Business Development, first at OSI Pharmaceuticals and later at Pfizer with responsibilities in the areas of CNS, ophthalmology and oncology. Lauren was also a Director of Strategic Alliances and Head of Cell Biology where she led multiple research teams after having been a founding scientist of Cadus Pharmaceuticals. Lauren was a postdoctoral fellow at Memorial Sloan Kettering Cancer Center and Princeton University and earned her Ph.D. in molecular biology from the University of Utah. She serves on the Business Advisory Board of the Epilepsy Research Foundation's Epilepsy Therapy Project, National Cancer Institute's SBIR review panel and Mass Life Sciences Center Scientific Advisory Board. Dr. Silverman also serves on the Steering Committee for the Brigham and Women's Hospital. Lauren currently serves on the Boards of Directors of the Novartis Venture Funds portfolio companies: Ra Pharmaceuticals, Inc., Proteostasis Therapeutics, Pulmatrix Inc., Viamet Pharmaceuticals, Inc., and Aerpio Therapeutics.
Andrey Zarur, PhD - CEO, BioProcessors
Dr. Zarur is a seasoned entrepreneur with over 10 years of international industrial and academic experience. He has participated in the start-up process of several biotechnology and engineering companies, both as operational executive and as member of the Board of Directors.
Prior to founding BioProcessors, Dr. Zarur served as C.O.O. of Starlab, a European fundamental research company. At Starlab Dr. Zarur also managed the Life Sciences Department with an emphasis on functional genomics, proteomics and bioinformatics. He also co-founded two ventures in Latin America, providing consulting and engineering services to the oil and pharmaceutical industries. Previously he was R&D Brand Manager for Health-Care products at Procter & Gamble Latin America.
Dr. Zarur earned his Ph.D. in Chemical Engineering and Master's degree at the Massachusetts Institute of Technology. He has authored several refereed papers and patents, and has been the recipient of various prestigious scientific and management awards.
An intimate discussion
The Convergence Dinner Series continues the conversations that take place each year at the Convergence Forum. Each dinner brings together a targeted group of executives to share their experiences and debate a topic with a well-known moderator. The dinners are invitation-only and are limited to no more than 30 executives from life sciences companies. To request an invitation, please contact Alyssa Stern. For information about sponsorship, please contact Shayne Gilbert.
This dinner program was a joint venture of L.E.K. Consulting and Convergence: The Life Sciences Leaders Forum. The off-the-record conversation discussed questions such as: How are the terms, expectations, and milestones related to partnerships between life sciences companies changing? What are the hidden pitfalls, and the new definitions of success? The discussion was led by Jason Rhodes, President of Epizyme, and Laurence Reid, PhD, Chief Business Officer of Alnylam and moderated by Katrine Bosley, former CEO, Avila Therapeutics and Entrepreneur-in-Residence, Broad Institute of MIT & Harvard.
This dinner discussion was led by a panel of CEOs who discussed the nuances of getting initial funding in 2009, and securing follow-on funding in biotech, combination products, and med devices, specifically what do you need to know, and what milestones do you need to hit to maintain your funding momentum? Speakers include:
- Frank Bobe, CEO, Entra Pharmaceuticals
- Michael Gilman, PhD, CEO, Stromedix
- Stuart Randle, CEO, GI Dynamics
- Warwick Tong, Sr. VP of Development, Surface Logix
- Joseph Yanchik III, CEO, Aileron Therapeutics
- Moderated by Maggie LeFlore, PhD – Managing Director, MedImmune Ventures
This evening's dinner discussion was focused on the coming wave of diagnostic products. What new opportunities do they create for collaboration and partnership with makers of drugs and devices? How will they change the way healthcare is delivered? The dinner discussion was led by:
- Rich Kivel, CEO, TheraGenetics (moderator)
- Michael Magliochetti, CEO, Claros Diagnostics
- John McDonough, CEO, T2 Biosystems
- Dan Rippy, CEO, Allegro Diagnostics
This evening's dinner discussion was focused on what's new in Boston's research labs, what's in the process of being commercialized, and how the process of licensing IP is changing. It was led by:
- Noubar Afeyan, Managing Partner, Flagship Ventures (moderator)
- Lauren Foster, Assistant Director of Biotechnology, MIT Technology Licensing Office
- Nina Green, Director, Tufts University Office of Technology Licensing and Industry Collaboration
- Bruce Zetter, PhD, Vice President for Research and CSO, Children's Hospital Boston.
Three serial founders/CEOs from the life sciences realm shared their experiences — positive and negative — working with investors, building high-powered teams, structuring partnerships, and getting innovative products across the finish line. This evening's dinner discussion was led by:
- Alan Crane, CEO, Tempo Pharmaceuticals; Formerly CEO of Momenta Pharmaceuticals and SVP at Millennium Pharmaceuticals
- Paul Rubin, MD, CEO, Resolvyx Pharmaceuticals
- Formerly CEO of Critical Therapeutics and EVP of Sepracor
- Amar Sawhney, PhD, CEO, iTherapeutix; Formerly CEO of Confluent Surgical and Technology Founder of Focal, Inc.
Participants of this evening's dinner discussed some of the issues that drug and device companies encounter once their product is approved, in particular getting it covered by payors, making patients aware of it, and getting doctors to prescribe it.
This evening's dinner discussion was led by:
- Burt Adelman, MD, EVP of Development, Biogen IDEC
- John Freedman, MD, Freedman Healthcare; former Medical Director at Tufts Health Plan
- Jonathan Gertler, MD, Managing Director, Leerink Swann & Co.
- Joseph Madsen, MD, Medical Director, Neurosurgical Clinic, Children's Hospital
On the evening of May 8th, a select group of CEOs, investors, and senior researchers from the private sector and academia gathered at historic Quincy Market for an invitation-only dinner. Held at the same time that BIO was held in Boston, it was a unique opportunity to socialize with forward-thinking executives from Boston and elsewhere, discuss the conference and industry dynamics, and make new contacts. A special gathering of an international group of executives, this dinner was extended to a larger group of approximately 250 participants.
This evening's dinner discussion was led by:
- Robert Gould, Vice President of Licensing and External Research, Merck Research Laboratories, Boston
- Jeremy Levin, Global Head of Strategic Alliances for the Novartis Institutes for BioMedical Research
- Phil Vickers, Vice President and Site Head of Pfizer's Research Technology Center.
Issues addressed at the dinner included: How do the local arms of large pharmaceutical companies work with smaller biotechs in the Boston area, and other local entities? Are there ways to improve these interactions? Do R&D and marketing partnerships have their roots here, or back at corporate headquarters?
This evening's dinner discussion was led by:
- Robert Gould, Vice President of Licensing and External Research, Merck Research Laboratories, Boston
- Jeremy Levin, Global Head of Strategic Alliances for the Novartis Institutes for BioMedical Research
- Phil Vickers, Vice President and Site Head of Pfizer's Research Technology Center.
Issues addressed at the dinner included: How do the local arms of large pharmaceutical companies work with smaller biotechs in the Boston area, and other local entities? Are there ways to improve these interactions? Do R&D and marketing partnerships have their roots here, or back at corporate headquarters?
Forging strong partnerships
Like our East Coast program, Convergence Forum West has brought together a select group of life sciences executives and company founders; heads of R&D, chief business officers, venture capitalists, investment bankers; and partnership execs at pharmaceutical companies to discuss and debate the most pressing topics of interest to the industry – topics like forging strong corporate partnerships; attracting funding from private and public sources; building successful research organizations; streamlining product development and approval; understanding the coming convergence of biology, software, and medical devices; and staying ahead of regulatory changes.
Trends & issues that impact growth
2007 Edition
The 2007 edition of the Convergence Guide: Life Sciences in New England provided a detailed look at the life sciences industry in New England, including biotech, medical device, and pharma activity, regional partnerships, policy issues, and university research initiatives. This special edition included a detailed analysis of New England's most influential venture capital firms, stem cell research initiatives, promising early-stage life sciences companies, large medical device employers, and pharma companies with outposts in the region. It also included interviews with executives such as Genzyme CEO Henri Termeer, Rib-X Pharmaceuticals CEO Susan Froshauer, venture capitalist Jonathan Fleming, and MIT researcher Robert Langer. Written by seasoned journalists and featured industry experts, The Convergence Guide delivers an unbiased perspective on the trends and issues that impact the growth of the life sciences in New England. This 64-page, softbound edition will be a valuable resource — and an enlightening read.
2006 Edition
Download a read-only excerpt from the 2006 edition.


text: $3.00 Off Any One Spectracide Weed & Grass Killer, Triazicide Or Bug Stop Item $3 off See It! About this Deal You can get this at Walmart for $2.88. Which makes this a money maker!!!! Flag this deal Edit deal What's the matter? Choose a reason Dead deal Duplicate Bad link Spam Inaccurate No value Alive again Comments

subset: commoncrawl


text:
Revolution and Development in an Asian Metropolis
Edited by Christopher Howe
Format: Hardback
Normal Price: $330.00
Your Price: $297.00 AUD, inc. GST
Shipping: $7.95 per order
You Save: $33.00! (10% off normal price)
Plus...earn $14.85 in Boomerang Bucks
Availability: Available to Backorder, No Due Date for Supply
Shanghai by Christopher Howe
Book DescriptionShanghai is Asia's largest city and for over a hundred years has played a critical role both in China's internal political arid economic affairs, and in the history of international relations in the Far East. Before 1949, Shanghai was the principal point of western and, later, Japanese penetrations of China. Under foreign control the city saw the beginnings of modern economic growth, of new forms of westernized education and culture, and of fierce social and political conflicts. This book is a comprehensive study of the way in which old Shanghai was transformed and developed by the Communist Party between 1949 and the later 1970s. It throws light on the paradox that a city that for years was the object of hostility and distrust has become in the Post-Mao era the spearhead of China's new programme for economic and technological modernization. The book is divided into sections dealing with political, economic and cultural change, and with the special characteristics of Shanghai's rural suburbia.
Buy Shanghai book by Christopher Howe from Australia's Online Bookstore, Boomerang Books.
Book DetailsISBN: 9780521231985
(216mm x 138mm x 30mm)
Pages: 464
Imprint: Cambridge University Press
Publisher: Cambridge University Press
Publish Date: 7-May-1981
Country of Publication: United Kingdom
Other Editions...
Books By Author Christopher Howe
Employment and Economic Growth in Urban China 1949-1957, Paperback (June 2010)
A study of China's urban employment problems set in the context of growth and fluctuations in the urban economy.
Wage Patterns and Wage Policy in Modern China 1919-1972, Paperback (March 2009)
This book provides an analysis of changes in the level and structure of wages in China from the 1920s to 1972.
Gene Cloning and Manipulation, Paperback (July 2007)
An updated edition of this concise guide to recombinant DNA techniques for advanced undergraduates.
Shanghai, Paperback (November 2006)» View all books by Christopher Howe
This book is a comprehensive study of the way in which old Shanghai was transformed and developed by the Communist Party between 1949 and the later 1970s.
» Have you read this book? We'd like to know what you think about it - write a review about Shanghai book by Christopher Howe and you'll earn 50c in Boomerang Bucks loyalty dollars (you must be a member - it's free to sign up!)
Facebook Page | Twitter | Google+ | Bulletin e-Newsletter | Blog | RSS
Become a Member | Book Lists | Recently Released | Coming Soon | Fast Delivery Books
Bestselling Books: Our Current Bestsellers | Australia's Hottest 1000 Books | Bestselling Fiction | Bestselling Crime Mysteries and Thrillers | Bestselling Non Fiction Books | Bestselling Sport Books | Bestselling Gardening and Handicrafts Books | Bestselling Biographies | Bestselling Food and Drink | Bestselling History | Bestselling Travel Books | Bestselling School Textbooks & Study Guides | Bestselling Children's General Non-Fiction | Bestselling Young Adult Fiction | Bestselling Children's Fiction | Bestselling Picture Books | Top 100 US Bestsellers
For: Schools | Organisations | Libraries | Publishers | Authors | Book Clubs | Bloggers | Affiliates
About Us | Contact Us | Help Desk | Security | Privacy | Terms of Use | Copyright
Phone: 1300 36 33 32 (9am-5pm Mon-Fri AEST) - International: +61 2 9960 7998 - Online Form
Address: Boomerang Books, 878 Military Road, Mosman Junction, NSW, 2088
© 2003-2017. All Rights Reserved. Eclipse Commerce Pty Ltd - ACN: 122 110 687 - ABN: 49 122 110 687
For every $20 you spend on books, you will receive $1 in Boomerang Bucks loyalty dollars. You can use your Boomerang Bucks as a credit towards a future purchase from Boomerang Books. Note that you must be a Member (free to sign up) and that conditions do apply.


text:
Compelling historical fiction based on the life of Lise Meitner, an early 20th century scientist. Read More »
Home / Tag Archives: Nuclear Fission
Nuclear Fission Power Plants and Transition to ITER and Fusion Nuclear Power
The evolution of fission nuclear power plants to the ITER fusion nuclear power plant. Read More »


text:
Video Friday: OED Videos
Dave Wilton, Friday, March 25, 2011
The OUP blog has put up three neat, little videos on one page that talk about updating the OED. They address updating the entries for potato salad and megalosaurus and adding new words to the dictionary.
Filed under: The Harmless Drudge
« Previous Entry | Main | Next Entry »
Powered by ExpressionEngine
Copyright 1997-2017, by David Wilton
Copyright 1997-2017, by David Wilton


text:
Need ad expert for website banner CONCEPT
This project received 3 bids from talented freelancers with an average bid price of $30 USD.Get free quotes for a project like this
Project Budget$30 - $250 USD
Total Bids3
Project Description
I need an advertising expert to develop a concept for a banner that simply and clearly describes a site like this freelancer site.
The concept must clearly communicate with a few words and visuals what this site does - **must be easy for new visitors to understand what this site does.
Target audience will be more of the employers side but must also be easy for freelancers to grasp the concept.
You do not need to design the banner. I JUST NEED A CONCEPT!
I am willing to pay $30 for a good concept so BID ONLY $30.
There is no way for me to know judge your creative capability off the bat so ... WITH YOUR PROPOSAL, PLEASE SEND ME JUST SOME TEXT IDEAS TO CLEARLY DESCRIBE THIS SITE.
I don't really need to know what projects you've done in the past but I need to know that you are capable of doing the task-at-hand.
If I find that your concepts are good then I will select you and open a milestone payment of $30 - and then you can give me some visual 'concepts' for the banner (not actual designs).
If you are a designer also, I may commission more work from you to design the banner but only after a satisfactory concept.
I look forward to your bid.
Skills Required
Looking to make some money?
- Set your budget and the timeframe
- Outline your proposal
- Get paid for your work
Hire Freelancers who also bid on this project
Looking for work?
Work on projects like this and make money from home!Sign Up Now
- Forbes
- The New York Times
- Time
- Wall Street Journal
- Times Online


text:
Drupal Themes - PSD - HTML Conversion - CSS - Front End - UI
This project was awarded to drupaldelhi for $90 USD.Get free quotes for a project like this
Project Budget$250 - $750 USD
Total Bids23
Project Description
Project Requirements: You must write and speak English for this project.
Please complete:
Microphone / Headset Working (Yes - No)
Speak English (Yes - No)
Broadband Internet Connection (Yes - No)
Must be Yes on all Project Requirements. Please respect your time.
We don't work with large firms.
We only work directly with Drupal UI Designer, not a project manager. This person is actually developing the php code vs. managing a team of engineers.
Please send 5 samples of your best Drupal themes you created.
PSD - HTML Conversion Expert
+ Make email layouts / templates from PSD and use email editing tools.
Drupal, PHP, HTML, CSS, Javascipt and jQuery.
You must be able to write new Drupal modules and themes.
Awarded to:
Skills Required
Looking to make some money?
- Set your budget and the timeframe
- Outline your proposal
- Get paid for your work
Hire Freelancers who also bid on this project
Looking for work?
Work on projects like this and make money from home!Sign Up Now
- Forbes
- The New York Times
- Time
- Wall Street Journal
- Times Online


text:
Roommateexpress.Com, roommate referral service, listed under "Roommate Referral Services" category, is located at Fort Lauderdale FL, 33311 and can be reached by 9547358000 phone number. Roommateexpress.Com has currently 0 reviews.This business profile is not yet claimed, and if you are the owner, claim your business profile for free. If you are not the owner you can invite this business to join by email or by phone.Browse all Roommate Referral Services in Fort Lauderdale FL. Discover census data for Fort Lauderdale, FL.
Back to Top


text:
Our Account Representatives are available Monday through Friday 8:30am EST - 6:00pm EST
And Saturday 10:00am EST - 3:00pm EST
Email or Live Chat Now
Returns & Exchanges, Website Help
Refine By:
Stack Chair, square back with hand hold, 33-1/8"H, 250 lb. capacity, upholstered seat and back, 2" thick high density foam padding, 18 gauge steel black frame with additional support bars and 14 welds, scratch resistance powder coated finish, black vinyl
Have a question?
Chat now with one of our representatives.
Support is OFFLINE
Leave A Message


text:
19429 Surnames | 123708 Records | 2647 Reunions
Dead Fred asks:Are you a Desperate Genealogist?
Click the e-book above for details!
Dead Fred's Genealogy Photo Archive, a free, fun photo genealogy research web site devoted to helping you visualize your heritage!
Get the latest info about DeadFred and MORE in our E-Newsletter Relatively Speaking.
Photo Thumbnail
Click image for
larger view.
9 photos in database by this submitter.
Order The Desperate Genealogist's Idea Book: Creative Ways to Outsmart Your Elusive Ancestors (eBook).You can also order The Desperate Genealogist's Idea Book in hardcopy format by clicking here.
Photo #81249
Last Name: Winter
First Name : Ignota
Middle Name: Elizabeth
Subject's City: Fort Wayne
Subject's State: IN
Subject's County: Allen
Subject's Country: United States
Date: 1941-1960
Photographer's City:
Photographer's State:
Nee: Winter
Type** : SNAP
Comments: Ignota Elizabeth Winter (Nee: Winter) | Fort Wayne IN United States | 1941-1960 | Comments: Ignota Winter Bodenhorn, wife of Frank Bodenhorn.
Digital Image Only?
Everyone Listed In This Photo:
To view all records posted by this submitter, click here:
Search Photos | Post Photos | Surnames | Mysteries | Annuals
Meet Fred | Testimonials | Media | Archivists | FAQs
Contact Us | Groups | Links | Your Own Search Box | Marketplace
Privacy Policy | Terms of Service
Free genealogy searches for those looking into their family history.
© 2001-2017 DeadFred.com Genealogy Photo Archive
P.O. Box 6937 | Springdale, AR | 72766-6937 | (479) 750-0082
Search Photos
Post Photos
Meet Fred
Media Center
Contact Us
Facebook Group
Your Own Search Box


text:
More Videos...
1996 Mercury Cougar XR7 Tour
A tour of my 1996 Mercury Cougar XR7 V6. I AM NOT claming/trying to be a saabkyle04 impersonater this was the easiest way I could think to do a tour of my car. He is an inspiration though.
mercury cougar 1997 smoked out
1997 mercury cougar xr7 in the works of becoming fresh
Jesse's 1996 cougar (muffler delete)
o ya 4.6l no muffler...nice and ghetto
1996 Cougar XR7 - PI Build/Swap w/ Magnaflow Exhaust System
This is a video of the start up of my built up ported PI engine, the Exhaust system, and a short drive off. This build took about a year in total, gathering parts, rebuilding the heads and putting it all together. I still need to get it Dynotuned but that will be for later on. It runs on 94 octane as I want to avoid pinging until i get a tune done. It was fun to see it all come together. Was a lot of work but I never gave up on the project. The Audio level is different in some clips as I used a different camera for them.


text:
The overall purpose of the Deep South RCMAR is to reduce health disparities between African American and White older adults in the region of the country where the majority of older African Americans (AAs) live and health disparities have been particularly persistent. The ultimate goal will be to eliminate such disparities. The proposed new Core D (Analysis Core-AnC) will support the activities of the Deep South RCMAR in the areas of measurement and secondary data analysis. The AnC will leverage existing expertise, data resources, and infrastructure at our four partnering institutions (Morehouse School of Medicine, Tuskegee University, the University of Alabama, and the University of Alabama at Birmingham) to enhance the capacity of the Deep South RCMAR to conduct research in the areas of measurement and secondary data analysis. To achieve our aims, we will pursue a three-fold strategy. First, we will advance science by conducting research and supporting research activities that involve: a) Assessing measurement equivalence of health-related measures for older African Americans in the Deep South;and b) Analyzing secondary datasets with a focus on older African Americans in urban and rural settings. Specifically, we will pursue two projects during the first 2-years of inclusion of the AnC in the Deep South RCMAR. One project will examine the measurement equivalence of CAHPS cultural competency and health literacy scales among older African Americans and Whites in Alabama, and the second project will focus on local area variations of health disparities by analyzing Medicaid data and other secondary datasets. Second, we will collaborate with the IDC and the CLC in the training and mentoring of Deep South RCMAR Scholars by conducting workshops in measurement techniques and secondary data analysis, and facilitating linkage of Scholars with methodological, biostatistical, and analytical resources. Finally, we will collaborate with the RCMAR Coordinating Center in the dissemination of culturally informed measures and secondary data analysis techniques relevant to minority aging.
There is a growing need for the development of culturally informed and scientifically valid measurement tools with a focus on older African Americans in urban and rural settings. Similarly, there is a significant need for secondary data analysis to inform the development and evaluation of interventions to address aging health disparities issues. The Deep South RCMAR is particularly well positioned to pursue these areas of research.
|Kim, Giyeon; Shim, Ruth; Ford, Katy L et al. (2015) The relation between diabetes self-efficacy and psychological distress among older adults: do racial and ethnic differences exist? J Aging Health 27:320-33
|Caplan, Lee; Sawyer, Patricia; Holt, Cheryl et al. (2014) Religiosity After a Diagnosis of Cancer Among Older Adults. J Relig Spiritual Aging 26:357-369
|White, Laura; Ford, Matthew P; Brown, Cynthia J et al. (2014) Facilitating the use of implicit memory and learning in the physical therapy management of individuals with Alzheimer disease: a case series. J Geriatr Phys Ther 37:35-44
|Sadasivam, Rajani S; Luger, Tana M; Coley, Heather L et al. (2014) Robot-assisted home hazard assessment for fall prevention: a feasibility study. J Telemed Telecare 20:3-10
|Kim, Giyeon; Parmelee, Patricia; DeCoster, Jamie et al. (2014) The relation between body mass index and self-rated mental health among older adults: do racial/ethnic differences exist? Am J Geriatr Psychiatry 22:661-9
|Bowling, C Barrett; Muntner, Paul; Sawyer, Patricia et al. (2014) Community mobility among older adults with reduced kidney function: a study of life-space. Am J Kidney Dis 63:429-36
|Petrov, Megan E; Sawyer, Patricia; Kennedy, Richard et al. (2014) Benzodiazepine (BZD) use in community-dwelling older adults: Longitudinal associations with mobility, functioning, and pain. Arch Gerontol Geriatr 59:331-7
|Pisu, Maria; Martin, Michelle Y; Shewchuk, Richard et al. (2014) Dealing with the financial burden of cancer: perspectives of older breast cancer survivors. Support Care Cancer 22:3045-52
|Kim, Giyeon; Parton, Jason M; Ford, Katy-Lauren et al. (2014) Geographic and racial-ethnic differences in satisfaction with and perceived benefits of mental health services. Psychiatr Serv 65:1474-82
|Kutner, Nancy G; Zhang, Rebecca; Allman, Richard M et al. (2014) Correlates of ADL difficulty in a large hemodialysis cohort. Hemodial Int 18:70-7
Showing the most recent 10 out of 43 publications


text:
Hotels in Aransas Pass, Texas
Search & Compare Aransas Pass Hotels
Get Secret Prices on select hotels
These prices aren't available to everyone.
Trending now in Aransas Pass
Hotels in Aransas Pass
- Most bookedHawthorn Suites by Wyndham Aransas Pass
47 people looked at this hotel in the last hour
Most recent review
"Was very impressed & will come back again. Breakfast was really good"
A Traveller, Jan 2017, US
43 people looked at this hotel in the last hour
Most recent review
"We love going down during the holidays, it's so quiet and peaceful at the beach this time of year. No crowds, no lines. Even the Ferry was a breeze to get across. And deserted fishing piers. Perfect <3"
A Traveller, Dec 2016, US
- Fairfield Inn & Suites Corpus Christi Aransas PassNo Guest Reviews yet
23 people looked at this hotel in the last hour
21 people looked at this hotel in the last hour
Most recent review
"HOTEL WAS CONVIENIENT TO THE BRIDGE THAT GOES TO Port Aransas BEACH. HEB GROCERY STORE ACROSS THE STREET. room was comfortable. bed was very comfortable. Good tile flooring. Clean. Good continental breakfast along with waffle. Lots of TV cable stations. "Bianca" the evening receptionist was extr..."
A Traveller, Oct 2016, US
9 people looked at this hotel in the last hour
8 people looked at this hotel in the last hour
Hotels within 5 miles of Aransas Pass
26 people looked at this hotel in the last hour
Most recent review
"They helped me with my little dog, & in short, helped me instead of penalizing me for not being to be there on expected day in such short notice. I was to arrive one day--& in manner of hours the day before arrival, needed to change it to the following day leaving me with a one night instead of 2..."
A Traveller, Jan 2017, US
21 people looked at this hotel in the last hour
Most recent review
"We were in south Texas for a family reunion. The hotel wasn't too far away from the reunion site and was perfect for our family. The staff was fantastic!, as well as the accommodations, breakfast, just everything!!"
A Traveller, Nov 2016, US
16 people looked at this hotel in the last hour
Most recent review
"Pleasant stay with a friendly staff. Rooms are a decent size with free cable and WiFi."
A Traveller, Aug 2016, AS
5 people looked at this hotel in the last hour
Most recent review
"We stayed in the fully equipped kitchen king bedroom. This room was nice and truly equipped the bathroom and bed were very nice clean over all loved it. the entrence was a little tricky was kinda small but nothing wrong. Oh yes great breakfast not like other places they had a great variety. They ..."
A Traveller, Aug 2015, US
Best hotels in Aransas Pass
Aransas Pass overviewAransas Pass is a budget-friendly place distinct for its beaches and known for its ferries and port. You'll enjoy the ample coffee and bar choices, along with activities like boating and fishing. Take in some local culture at popular places like USS Lexington Museum on the Bay and Art Museum of South Texas. Texas State Aquarium and Corpus Christi Museum of Science and History are popular sights to see. A family-friendly area, Aransas Pass also has something for everyone.
Where to stay in Aransas PassA welcoming city for all, Aransas Pass has a variety of lodging options. There are 122 hotels in the Aransas Pass area and you can shop as many as 38 deals for rooms on Hotels.com, some with discounts of up to 45%.
- • 48 2-star hotels with an average price of $59 per night
- • 58 3-star hotels with an average price of $76 per night
- • 11 4-star hotels with an average price of $79 per night
Here are the top hotels based on 21967 user reviews of Aransas Pass hotels:
- • Microtel Inn & Suites by Wyndham Aransas Pass/Corpus Christi (Aransas Pass)
- • Hawthorn Suites by Wyndham Aransas Pass (Aransas Pass)
- • Super 8 Aransas Pass Tx (Aransas Pass)
- • Americas Best Value Inn & Suites (Aransas Pass)
- • T&G Vacation Properties (Aransas Pass)
How to get to Aransas PassFly in to Corpus Christi, TX (CRP-Corpus Christi Intl.), 23.6 mi (37.9 km) from downtown Aransas Pass.
What to see around Aransas PassFun activities such as boating, ferry rides, and exploring the port are at hand, along with attractions such as:
- • Horace Caldwell Pier
- • Key Allegro Marina
- • Corpus Christi Marina
- • Aransas Pass Aquatic Center
- • Aquarium at Rockport Harbor
- • Texas State Aquarium
- • Hurricane Alley Waterpark
- • USS Lexington Museum on the Bay
- • Art Museum of South Texas
- • Corpus Christi Museum of Science and History
When to visit Aransas PassIf you're starting to plan your trip, you might be wondering when's the best time to visit. Here are the seasonal norms to help you decide when to go:
Seasonal temperature averages
- • January-March: 74°F day, 50°F night
- • April-June: 89°F day, 63°F night
- • July-September: 90°F day, 74°F night
- • October-December: 85°F day, 51°F night
- • January-March: 7.1 inches
- • April-June: 8.3 inches
- • July-September: 10.5 inches
- • October-December: 8.8 inches


text:
French Country Renaissance Carved Wood Antique Gold Candle Holder - Set of 5
We all look better by candlelight, and this collection of five rustic candlesticks will bathe you in enough soft light to make you catalogue worthy. With hand- ... more
- Sizes range from 14 inches high x 5 inches wide x 5 inches deep to 28 inches high x 8 inches wide x 8 inches deep
- Constructed from mango wood
- Distressed hand-rubbed finish with gold accents
- Each candlestick features unique carved design
- Top of each candlestick features spike to secure candle
- Part of the FRENCH COUNTRY Collection
- Free Standard Shipping.
SHIPPINGFREE Standard Shipping on all orders within the contiguous US. Premium white glove delivery available for additional shipping fee. Learn more
DELIVERYShips within 5 business days. Please allow up to 1 additional week transit time for your item to arrive.
RETURNSReturns are accepted within 30 days of delivery. Restocking fees may apply. Please read our returns policy in full here.
Have a question about this product? Ask Us
All form fields are required.


text:
It's time to close this chapter. After I decided to close my art portfolio lifelines, I wanted a fresh start. That's why I created a new graphic journal: afternoonhigh.
Even though nightfall_icons is closing, I won't delete it. But the icons will disappear soon (red crosses will appear), so snag what you want/need before it is too late. Don't expect me to reply to your comments from now on though.
The mood themes(!), caps and resources can still be downloaded since I haven't uploaded these to my server. These are safe.
I wanna say thank you to every single one who commented, credited and encouraged me during these 5 years. I feel honored. And it has been a pleasure. This is the end, but not a goodbye!
I hope to see you over at afternoonhigh. Feel free to add this comm for updates. Thank you for everything. *hugs*


text:
Bill Meyer wrote:
> I think we hosta fans need a candidate of our own. Someone who
> understands us and will push for policy changes to make our lives easier. We
> need a president who gardens. A president that worries about overwintering
> and can't wait for spring. A president that will surround the White House
> with hostas and other (companion) plants. A president that also worries
> about viruses and nematodes. A president who can tell organic fertilizer
> from campaign speeches. Yes, we need a president who cares about the plants!
I agree, and I also think the Hair Factor is somehow important. That said, how
about a woman with a big old head of hair and a working knowledge of hostas?
Ubi sunt qui ante nos fuerunt,
Kristi A. Groberg, Ph.D.
To sign-off this list, send email to email@example.com with the
message text UNSUBSCRIBE HOSTA-OPEN


text: Outdoor PlayFor kids who love to spend time outside, Rosenberry Rooms Outdoor Play collection offers play furniture from top quality brands. Kids tables are great for outdoor arts and crafts or for seating for a neighborhood barbecue. For summer and spring play dates, your little ones can have all the fun of the beach without ever having to leave the backyard. Rosenberry Rooms also offers kid-sized outdoor chaises and Adirondack chairs that are perfect for an afternoon nap after a long and exciting day of outdoor play!


text:
wendy wellness mac download - download fast -=pIFl=-
wendy wellness mac download.zip - download 2015
Name: wendy wellness mac download.zip
Release: 2015
Type: WinZip
Total Downloads: 14196
License model: Shareware
Language: English
Last updated on: 01/26/2015 13:53:10
Supported OS: Windows 8, Windows 7, Windows Vista, Windows XP
Keys:01/26/2015 13:53:10
Wendy's Wellness Game Download for PC! Build up your own wellness center! Download Wendy's Wellness for PC for free!Wendy's Wellness Game Download for Mac! Build up your own wellness center! Download Wendy's Wellness for Mac for free!Wendy's Wellness is a new time management game, which will definitely captivate you. Fitness meets fun in this Time Management adventure to restore the city's well-being.Wendy's Wellness is a new time management game, which will definitely captivate you. Fitness meets fun in this Time Management adventure to restore the city's well-being.Wendy's Wellness: Create your own chain of 10 splendid fully-equipped wellness centers, serve the customers, buy new equipment and hire employees. Discover the ...Wendy's Wellness Game Download on Arcade Town .comIn Wendy's Wellness Deluxe kannst du auf Zylom Zimmer einrichten! Wolltest du schon immer ein ganzes Haus oder andere Gebäude einrichten? Das ist deine Chance!Nutrition facts and Information for Wendy's side order: ChiliBuy Health Promotion Theory (Understanding Public Health) by Maggie Davies, Wendy Macdowall (ISBN: 9780335218370) from Amazon's Book Store. Free UK …Sister Wendy Beckett writes about art in a style that is idiosyncratic, fresh, and perceptive. In 1000 Masterpieces, she applies her unique intensity to what most ...
wendy wellness mac download
01/26/2015 13:53:10
nba live 2009 p h d biomedical program easter ccd book mark craft ncis los angeles s05e15 publichd the notebook like myspace song bluest eyes in texas how to pitt a peach tom tom for htc how to improve fitness level quickly dandy-119 mirai torrent rhapsody book series new installing a game patch armour packing plant in chicago boondocks tjeme song how to use ligatures song lyrics bits and pieces new future mp3 mp3 chick gets nailed blues brothers songs mising from ost kv 32cs70 manual margherita 2000 pdf proshowgold crack keygen xfx ati radeon hd 4650 vista cnc router and automatic edgebander package w audio4fun commp3 playermp3 player download htm scarf it torrent discount tickets to broadway shows sydney how to fix a decaying tooth adult funnies games service manual book


text:
On Language; Let Forthcoming Come Forth
Published: May 12, 1991
"THE EMIR AND THE crown prince were very forthcoming ," said Secretary of State James A. Baker 3d, using one of the most frequent words in the vocabulary of diplomacy. It means "open to new ideas, cooperative, willing to bring helpful suggestions to the negotiations."
In diplolingo, the antonym of forthcoming is frank , which in this limited sense means "surly, argumentative, intransigent and causing an obstacle to peace." A meeting described by a spokesman as a frank discussion is bad enough; a frank exchange verges on shouted recriminations and hints of war.
Forthcoming, however, is a compliment; in a recent political polemic, I fell into using it myself. That triggered this note from Sheila Davis of New York: "I've been saddened by the slow erosion of forthright . I was therefore stunned by your replacement of forthright by forthcoming ." She asks: "Is this a case of anxious/eager ? Are we about to read a new entry in our dictionaries under forthcoming -- 'synonymous with forthright '?"
Don't be anxious; I am eager to straighten this out.
Forthright means "straightforward, candid, without hesitation or guile," and in the nondiplomatic sense, "frank."
Forthcoming , however, has a couple of meanings: one is "about to appear, soon to be available, approaching"; the second sense of the word is forthcoming in the following sentence. That is the "open, cooperative, helpful" sense in diplolingo, usually marked in dictionaries as "chiefly British."
Controversy rages over that British sense. In "American Usage and Style: The Consensus," Roy H. Copperud (now the word columnist for Editor & Publisher) says, "The displacement of forthright (direct, straightforward) or, sometimes, outgoing (friendly, responsive) by forthcoming is regrettable and should be discouraged." Why? "It can cause ambiguity. . . . For example, 'The President's statement was forthcoming' could be understood to mean that it was about to be made, not that it was forthright."
I am ordinarily on the side of preserving distinctions, not because I am eager to please, but because I am anxious about fuzziness. The question before us is this: Does forthcoming in its "coming forth with ideas" sense fill a need for meaning that no other word offers?
It does. Let's say the emir, or whoever, is willing to go along with what you suggest. You, as a diplomat, cannot describe his attitude as responsive , which it is, because that makes it sound as if you are the one with the ideas and he's just sitting there, going along, responding to you. Helpful is patronizing, and too easily confused with unhelpful , a diplolingo staple meaning "I'm going to zap this guy for this"; friendly denotes the tenor of the talks but not the action of moving them forward.
If you want to indicate that the emir has also come forth with a helpful idea, or to cover his acquiescence in your proposal, the best word is forthcoming . It's best not because it contains no possibility for ambiguity -- on the contrary, it does confuse at times, as Mr. Copperud points out -- but because I cannot think of another word to describe the emir's willingness to help or even to be creative. Remember that it is used by diplomats to compliment the other guy in the meeting for his willingness to go along, or at least agree not to obstruct, while it also suggests that he came forth with an idea of his own.
Let lexicographers, then, drop the "chiefly British" (as the latest Random House Webster's College edition does) and forthrightly accept forthcoming with its two meanings. Let us hope that the forthcoming statement will show the emir to be forthcoming. Poetic Allusion Watch
LANCE MORROW IS ONE of the classiest stylists in the news-magazine dodge, because he spices his prose with poetic allusions. He does this subtly, with no quotation marks or "as the poet says," expecting readers of Time to catch, appreciate and be intellectually enriched by the oblique references; if the allusion slips by unnoticed, no harm is done to the flow of communication.
This department conducts a periodic Poetic Allusion Watch (PAW), which is not to be confused with a periodical PAW limited to magazines. The PAW division of the Lexicographic Irregulars has been letting down the side lately, requiring me to clamber up to the crow's-nest myself.
Consider "The Trouble With Teddy." (Time magazine's headline writers capitalize with but few other prepositions and articles; sometimes they capitalize of , sometimes not, but hobgoblins pay this little mind.) In his essay-article about Senator Edward M. Kennedy's current nocturnal tribulations, Mr. Morrow uses the metaphor of a shadow cast across a luminous life. "Was all this unhappy transformation the influence of metaphysics? Or was it alcohol? In any case, the shadow fell ."
That's a fairly easy catch. In "The Hollow Men," T. S. Eliot wrote, "Between the idea/And the reality/Be tween the motion/And the act/Falls the Shadow." This passage, derived by Eliot from "There fell thy shadow" in Ernest Dowson's poem to Cynara, is followed by a line from the Lord's Prayer, "For Thine is the Kingdom," an apt reference to the Kennedy reach for power and glory.
The next was slightly more obscure. "Perhaps his life was cracked after Bobby died," Mr. Morrow wrote, "and Teddy found he was on his own and began to cross over from the powerful myth of his family into real time, which is intolerant of the bright and ideal."
Nice. Real time , with its computerese sense of "processes that respond immediately to user input," seems only to contrast with the preceding powerful myth , but the sensitized eye sees it connected by poetic allusion to the subsequent intolerant . Language mavens are especially likely to know that this comes from W. H. Auden's 1940 memorial to William Butler Yeats: Time that is intolerant Of the brave and innocent, And indifferent in a week To a beautiful physique, Worships language and forgives Everyone by whom it lives. . . .
Mr. Morrow, or the Time copy editor, changed Auden's "Time that" to "time, which"; apparently they are especially sensitive at Time to relative pronouns that stand for their magazine's name. (They should devote that attention to taking a stand on the capitalization of of in headlines.)
When a writer makes two allusions in a piece, the odds are that he will make a third; some sort of inner need to accomplish a hat trick drives us all. I searched for the third, centered on "He had to soldier on in the messy world after Camelot floated away into memory," but found no Kipling reference under soldier on or messy world in any of the quotation-book indexes. (That's the trick in tracking poetic allusions; don't trust your memory.)
So I called Lance Morrow and laid the PAW on him.
"I only realized I was making the allusions afterward," he replied. "It wasn't entirely advertent. But then I said, what the hell, leave them in."
So where is the third one?
" Cracked ," he murmured.
Of course; that was an odd verb to use to describe a life, and PAW should have caught it. "Perhaps his life was cracked" is bottomed on the poet-philosopher Ralph Waldo Emerson's "There is a crack in every thing God has made." Whoso would be a PAWperson must be an Emerson student; he's the same fellow who linked the hobgoblin of little minds to a foolish consistency.


text:
|Message view
|« Date » · « Thread »
|« Date » · « Thread »
|Kelly Denehy <kden...@gmail.com>
|Re: AW: How many connections can be made to Tomcat on Windows?
|Tue, 14 Sep 2004 17:53:24 GMT
On Tue, 14 Sep 2004 19:00:06 +0200, SH Solutions <email@example.com> wrote: > Hi > > > in the even you're using windows professional, it is limited to 10 inbound > connections, which is easy to overlook and forget. > > NO. > The limit of 10 inbound connections apply to _windows shares only_. It's a > limitation to prevent usage of "professional" as "server". > > However, the tcp/ip stack of professional and server are the _SAME_ and > there is _NO_ limitation on incoming or outgoing connections, as long as the > hardware can handle them. > > One exception: Windows xp sp2 has a limit for the rate of creating outgoing > connection, which is suppost to slow down worms, but it can be disabled in > registry. However, this does NOT apply to incoming connections. > > However, 1000 request/second is propably way to much for one system. Buy two > and use load balancers, or do very good cashing in your webapp. But do not > access the database for every page hit. > > Regards, > Steffen > > --------------------------------------------------------------------- > To unsubscribe, e-mail: email@example.com > For additional commands, e-mail: email@example.com > > >From a *technical* standpoint, you are correct regarding socket connections. From a *legal* standpoint, however, the EULA for the Workstation product limits you to 10 concurrent socket connections, in order to try to force you to use Server instead. MS changed this back around NT 4.0 because people were putting http servers on NT Workstation instead of NT Server to save money. --------------------------------------------------------------------- To unsubscribe, e-mail: firstname.lastname@example.com For additional commands, e-mail: email@example.com
|View raw message


text:
Visit our other Wisconsin Historical Society websites!
Refine or narrow your results by clicking any term in the gray boxes below.
Expand your results by removing any breadcrumb in a gray outlined box above. Click on the blue "X" to remove the term.
Narrow your results by entering a keyword into the search box above. Then click the "Search Within" checkbox, then click on the orange "Search" button.
If you did not find what you are looking for or you did not get any results, try changing your search term(s). See our Search Help page for more tips.
Date: 1956
Description: The old YMCA building in the initial stage of demolition.
Date: 1924 after
Description: This pictorial map focuses on the Madison Isthmus, Lake Mendota, Lake Monona, Lake Wingra, and shows points of historical interest, buildings, parks, and I...
Date: 1935 ca.
Description: The Insurance Building, located at 119-123 Monona Avenue.
Date: 1939 ca.
Description: View through trees from across a tree-lined Langdon Street of the YMCA. Part of the Armory (Red Gym or Old Red) is also visible on the right.
Date: 2008
Description: Clark Station located at 1129 South Park Street.
Date: 1936 ca.
Description: Post office and insurance buildings (on right), Monona Avenue and East Wilson Street. The Wisconsin State Capitol is visible in the background. A view of t...
Date: 1949 ca.
Description: View of the Wisconsin State Capitol from Lake Road, across Lake Monona. Two large trees frame the view of the Capitol.
Date: 1940 ca.
Description: Exterior view of the Wisconsin Telephone Company, 17 South Fairchild Street.
Date: 1897 ca.
Description: Three men, identified from left to right as Mr. Schildhauer, Mr. Parker, and Mr. Potter, at the Internal Revenue Office. The men are gathered around a larg...
Date: date unknown
Description: Haines Photo Co. panoramic photo of Madison's Capitol Square, taken from the King Street corner.
Date: 1904
Description: This map shows a plat of the west part of the city, numbered blocks and lots, some landownership, local streets, roads, railroads, wards by number, parks,...
Date: 1929 ca.
Description: Monona Avenue. The Wisconsin State Capitol can be seen in the background.
Date: 1890 ca.
Description: A drawing depicts the city of Madison.
Date: 1958-11-03
Description: An automobile rests on the sidewalk after running into the Wolff, Kubly & Hersig hardware store window at 30 North Carroll Street.
Date: 1981-05
Description: View across road of buildings at 202 - 222 East Washington Avenue including Pahl Tire Co., Paradise Printing and Federal Center.
Date: 1959 ca.
Description: Color postcard of the exterior of the Wisconsin Center for adult education at 702 Langdon Street.
Date: 1925
Description: 622 Mendota Court. This Mediterranean Revival fraternity house was designed by Law Brothers architects and erected in 1925 for the Beta Theta Pi chapter....
Date: 1910
Description: Winter scene of an unplowed, snowy Butler Street, Madison, Wisconsin, with tire tracks and snow-covered trees.
Date: 1885
Description: View down Bascom Hill of Science Hall (1876-1884) in the process of being demolished.
Date: 1925-12
Description: Exterior view from street of Madison Motor Car Company, 325 W. Gorham Street.
If you didn't find the material you searched for, our Library Reference Staff can help.
Call our reference desk at 608-264-6535 or email us at:
© 1996-2017 Wisconsin Historical Society, 816 State Street, Madison, WI 53706


text:
SDG enables an enterprise to manage risk—business, operational, program, and regulatory Risk through our innovative Advisory and Technology Services, and software solutions. We distinguish ourselves by offering a flexible business model to fit client needs; a go-to-market approach with an experienced and broad-based foundation of domain experts, deep program management expertise and a focus on minimizing risk to drive corporate growth.
SDG teams are led by subject matter experts who bring deep insight and experience to every engagement. Driven by a passion for solutions, we leverage best of breed technologies and focus on execution to deliver results for every client we engage. We are organized around six innovative practices: Risk and Compliance, Identity and Access Management, Enterprise Mobility, Cloud Computing and CRM, Collaboration and eCommerce and Quality Assurance.
53 State Street, 10th Floor
Boston, MA 02109
United States
Phone: 888-922-7842
Map: Google MapsView other locations


text:
Milford in New Haven County, Connecticut — The American Northeast (New England)
Milford World War II Memorial
Who Served
1941 1945
World War II
Location. 41° 13.305′ N, 73° 3.472′ W. Marker is in Milford, Connecticut, in New Haven County. Marker is at the intersection of Broad Street (Connecticut Route 162) and Armory Lane, on the left when traveling north on Broad Street. Click for map. Located on the Milford Green. Marker is in this post office area: Milford CT 06460, United States of America.
Other nearby markers. At least 8 other markers are within walking distance of this marker. Milford (within shouting distance of this marker); Milford Volunteer Fire Department (within shouting distance of this marker); Milford Memorial Flag Pole (about 300 feet away, measured in a direct line); Soldiers' and Sailors' Monument (about 500 feet away); Landing Site (about 600 feet away); Milford Memorial Stone Bridge (about 700 feet away); Simon Lake's Explorer Submarine (about 700 feet away but has been reported missing); Milford Korea - Vietnam Monument (about 800 feet away). Click for a list of all markers in Milford.
Additional comments.
I wanted to thank you for having this on line and for Michael Herrick to have the taken the photos. I recently began a search for my grandfather.
— Submitted March 29, 2012, by Angela Hope McElwain of Clarksburg, West Virginia.
Categories. • War, World II •
Credits. This page originally submitted on , by Michael Herrick of Southbury, Connecticut. This page has been viewed 1,176 times since then and 12 times this year. Photos: 1, 2, 3, 4. submitted on , by Michael Herrick of Southbury, Connecticut. 5, 6, 7, 8. submitted on , by Zeke Ferrante of New Fairfield, Connecticut. 9. submitted on , by Michael Herrick of Southbury, Connecticut. • Bill Pfingsten was the editor who published this page. This page was last revised on June 16, 2016.


text:
Arabi, GA Rent to Own Homes
|4 Listings Found
leases are nearby , golfing is right down the road and award winning restaurants are a easy drive away
181 Smokehouse Road, Cordele, GA, 31015Details »
. 2 billboards leased that provide income. Owner will sell as a whole or divide. Former Serro
Ashburn, GA, 31714Details »
with existing concrete slabs 3) 1 lot with independent cook shed 3 additional permanent buildings for rent: 1
Vienna, GA, 31092Details »
for yourself or lease the hunting rights for income. This property is completely timbered, and all planted pine
Rochelle, GA, 31079Details »
RentUntilYouOwn.com is the #1 provider of Arabi, Georgia rent to own homes listings.
Our goal is to offer the highest quality results, along with helpful Arabi resources and support. We understand that finding genuine rent to own homes in Arabi can be very difficult. Even more challenging is trying to search Arabi, GA listings for free.
After discovering how difficult it was for Arabi buyers and sellers searching online, RentUntilYouOwn.com has become dedicated to providing users with the most current, accurate, and detailed listings in Arabi, Georgia.
If you have any questions or suggestions for improving our site, please contact us here.
Trouble Finding Local Rent to Own Homes Listings?
If the initial results in Arabi, Georgia did not provide any listings of interest, or you just want more selections, click any of the blue tabs just above the search results for more.
Thanks for visiting and good luck!


text:
From deep within my heart.
© Copyright 2017 mum55. All rights reserved.
Status: Finished
Genre: Other
this is cute
good job
love the kiss stanza
feel free to check out my works
Good work Juliet, keep it going
Ahhhhhh AHA! ok, are you in looooooove ;=) Juliet?
you've been off falling in loooooove, and now are back to tell us all about it yah? ;=)
well I hope so, but if not, this poem sure is beautiful.
is Great to see you hun.
A wonderful way to describe love and what youre feeling! You've done a nice job on this one! Is it okay if I use your picture on a poem I have in mind? Would love to if I could! :)
Book / Fantasy
Short Story / Humor
Short Story / Mystery and Crime
Paste the link to picture in the entry below:
Paste the link to Youtube video in the following entry:
Cannot annotate a non-flat selection. Make sure your selection starts and ends within the same node.
An annotation cannot contain another annotation.
There was an error uploading your file.


text:
+ Reply
Results 1 to 3 of 3
- 06-21-2014, 03:14 PM Thread Author #1
Unlock/Lock button - not working
Hello guys!
So, here's the deal - I've accidentally glued the lock/unlock button on my phone. The phone is still working perfectly fine but I can't unlock it unless someone has called me or if I put a charger in. (It's an htc wildfire if that helps) So, my question is - Is there a way to change the lock/unlock button? (For example is there a setting/hack so that I can unlock my phone from the volume buttons or the motion button)
- Posts
- 4,711 Posts
- Global Posts
- 4,726 Global Posts
- Mentioned
- 0 Post(s)
- Tagged
- 0 Thread(s)
- Carrier
- Kitkat
Re: Unlock/Lock button - not working
Is the phone rooted? If it is, you can try this: http://forum.xda-developers.com/showthread.php?t=850464
You can map out what button does what. In this case, you can say a volume button can turn off the phone.
- Posts
- 78,011 Posts
- Global Posts
- 78,049 Global Posts
- Mentioned
- 6 Post(s)
- Tagged
- 0 Thread(s)
Re: Unlock/Lock button - not working
Welcome to Android Central! What kind of glue was it? Are there any solvents that might break it down?
In order to remap the hardware buttons, you'd have to root the device. Here's an article that discusses it. How to Remap the Hardware Buttons On Your Android Phone
Similar Threads
Not receiving group messages from iphones, I have always had androidBy Mort5428 in forum Ask a QuestionReplies: 2Last Post: 08-19-2014, 04:07 PM
SMS keeps bypassing my lock screenBy Ineed911 in forum HTC One M8Replies: 1Last Post: 06-21-2014, 03:05 PM
Multiple lock screen pages?By psychspirit in forum Samsung Galaxy S5Replies: 0Last Post: 06-21-2014, 02:41 PM
The phone has to be unlocked to access SVOICE or Goog. Now, correct?By U4icLab in forum Samsung Galaxy S5Replies: 1Last Post: 06-21-2014, 01:50 PM


text:
Philanthropy is possible through all levels of giving—we all have the ability to affect change in a profound way. For those who are able to make leadership level gifts ($1,000 or more) to the Anchor Fund, the University of Hartford recognizes them through the Harrison Scholars.
As a member of this group, your generous commitment will inspire, motivate and lead your peers in helping provide access to a University of Hartford education for those from even the humblest of backgrounds.
Consider leading the way by joining the Harrison Scholars today!
Donors who pledge $1,000 or more to the Anchor Fund for two years will receive special updates and communications. Call Jennifer B. Keyo, director of annual giving, at 860.768.2417 for more information.
Cumulative gifts throughout the fiscal year that reach $1,000 or more are also considered in the Harrison Scholars.